Pancreas Cancer Clinical Trial
Official title:
Multicentric Randomized Study Comparing the Histological and Molecular Material Quality Obtained by EUS-FNB of Pancreatic Mass With Two "Biopsic" Needles: the 20-gauge Procore® (Cook) and the 22-gauge Acquire® (Boston Scientific)
Multicenter randomized prospective study
Criteria for inclusion:
Patients admitted for EUS-FNB of a pancreatic mass
Goals of the study:
To compare the results of blinded punctures for suspicion of pancreatic tumor performed under
endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris
Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with
the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.
Main criterion:
- Biopsy core length of target tissue obtained by needle pass
Number of patients:
60 patients
Duration of the study:
1 year
Type of study:
Multicenter randomized prospective study
Criteria for inclusion:
Patients admitted for ENDOSCOPIC ULTRASOUND FINE NEEDLE BIOPSY (EUS-FNB) of a pancreatic mass
Exclusion criteria:
Patients with an extra-pancreatic mass puncture Echendoscopic puncture contraindication or
vascular interposition
Goals of the study:
To compare the results of blinded punctures for suspicion of pancreatic tumor performed under
endoscopic ultrasound in our center (Digestive Endoscopy Unit of the Digestive Pole Paris
Bercy, PDPB), in terms of diagnosis and quality of histopathological material obtained with
the help of 20G Procore, Cook and 22G Acquire needles, Boston Scientific.
Evaluation criteria :
Main criterion:
- Biopsy core length of target tissue obtained by needle pass
Secondary criteria
- Presence of a core biopsy specimen
- Sensitivity of EUS-FNB for the diagnosis of adenocarcinoma of the pancreas
- False negative rate, Negative predictive value for the diagnosis of pancreatic
adenocarcinoma
- Computer Aided Morphometric Evaluation of the Tumor + Stroma Surface on All core biopsy
specimens
- Success rate of isolation of tumor cells and determination of transcriptomic signatures
of pancreatic adenocarcinoma subtypes
- Immediate complications of puncture
- Variation in the quality of the puncture following the trans-duodenal or trans-gastric
access route
- Technical failure rate of puncture
- Optional: inter and intra-observer evaluation of the anatomopathological criteria used
(presence of a biopsy core, length of target tissue core per needle passage)
Number of patients:
60 patients
Duration of the study:
1 year
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT05435053 -
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05048524 -
Peri-operative SLOG for Localized Pancreatic Cancer
|
Phase 2 | |
Suspended |
NCT05124743 -
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
|
||
Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
Recruiting |
NCT05501379 -
Comparison of the Physical Activity in Cancer Patients Assessed by Questionnaire and Motion Tracker
|
||
Recruiting |
NCT04851106 -
Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.
|
||
Enrolling by invitation |
NCT04466189 -
Prospective Cohort Study of Pancreatic Cancer Patients Treated With Proton Beam Therapy
|
||
Terminated |
NCT01313416 -
Gemcitabine and CT-011 for Resected Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT01411072 -
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer
|
N/A | |
Active, not recruiting |
NCT01448668 -
Iscador Qu as Supportive Treatment in Pancreatic Cancer (Union for International Cancer Control, UICC Stages II-IV)
|
N/A | |
Completed |
NCT01155882 -
Registry Study - Whipple at the Splenic Artery
|
||
Recruiting |
NCT04970056 -
Pancreatic Cancer Early Detection Consortium
|
||
Recruiting |
NCT04140526 -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
Recruiting |
NCT06036563 -
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
|